


Products for FISH analysis

Breast Cancer Interpretation Guide



According to the NEW ASCO/CAP Guidelines 2018



Breast Cancer Interpretation Guide

ERBB2 (a.k.a. HER2) testing must be requested on every primary invasive breast cancer. Additionally, it is recommended to perform ERBB2 testing on metastatic sites, classified as stage IV, if tissue sample is available. This is to guide decision to pursue ERBB2-targeted therapy.

This Interpretation Guide is based on ASCO (American Society of Clinical Oncology) and CAP (College of American Pathologists) recommendations for ERBB2 testing in breast cancer (Wolff AC, et al. 2018)*.

It does not claim to be complete in reference to clinical usage and appraisal of results. Moreover, it should be regarded as a practical help of ERBB2 FISH evaluation in regards to clinical decision making.

What's New?


- Revised definition of IHC 2+ (equivocal) cases as invasive breast cancer with "weak to moderate complete membrane staining observed in > 10% of tumor cells".
- If the initial ERBB2 test result in a core needle biopsy specimen of a primary breast cancer is negative, a new ERBB2 test on a surgical specimen is no longer stated as mandatory.
- Less common FISH patterns should be reviewed by IHC using the same tissue sample:
 - 1) ERBB2/CEN 17 ratio of \geq 2.0 with an average ERBB2 gene copy number of < 4 signals/nucleus (FISH group 2)
 - 2) ERBB2/CEN 17 ratio of < 2.0 with an average ERBB2 gene copy number of \geq 6 signals/nucleus (FISH group 3)
 - 3) ERBB2/CEN 17 ratio of < 2.0 with an average ERBB2 gene copy number of ≥ 4 signals/nucleus (FISH group 4)

IHC results:


- a) IHC result is 3+: ERBB2 positive
- b) IHC result is 2+: Recount at least 20 cells by FISH in the IHC 2+ staining area by an additional observer. New FISH category or ERBB2 diagnosis is negative (FISH group 2+4)/positive (FISH group 3)
- c) IHC result is 0 or 1+: ERBB2 negative
- The concomitant IHC review for ISH group 2 to 4 is recommended to be performed in the same institution to ensure parallel interpretation and quality of the two assays.
- The usage of a dual color ISH probe is recommended by the Expert Panel instead of using a single color ISH assay.
 Concomitant IHC review becomes part of the interpretation of single color ISH results.

Evaluation Procedure


- 1. Localize the invasive component of a breast cancer specimen on a corresponding H&E or IHC slide.
- 2. Screen the entire slide prior to FISH signal counting for areas of aggregate population of ERBB2 amplified cells.
- 3. The area for counting should include clearly distinguishable and good distributed nuclei.
- 4. Count at least 20 non-overlapping cells in two separate areas of a population of tumor cells in the invasive component of the carcinoma (at least 10 cells per area). If there is a second population of tumor cells with increased ERBB2 signals per cell comprising > 10% of tumor cells on the slide, perform a separate counting of at least 20 cells within this cell population.
- 5. Determine the ERBB2 status according to the ERBB2 Interpretation Guide.
- 6. A second person should count an additional 20 non-overlapping cells if ERBB2/CEN 17 ratio is 1.8 2.2 and ERBB2 copy number is < 6.0.
- 7. Report if ERBB2 status is indeterminate due to e.g. artifacts, analytic testing failure, etc. or if ERBB2 status is discordant with other histopathologic findings and repeat test with another specimen.



Signal Interpretation Guide



Cell with autofluorescence



• Strong autofluorescence hinders signal recognition.

Autofluorescence - Do not count!

Zyto Light ® SPEC ERBB2/CEN 17 Dual Color Probe Kit

- Wash Buffer SSC
- ZytoLight ® SPEC ERBB2/CEN 17 Dual Color Probe



Prod. No.	Product	Label	Tests* (Volume)	
Z-2015-50	Zyto Light SPEC ERBB2/CEN 17 Dual Color Probe C € IVD	•/•	5 (50 µl)	
Z-2015-200	Zyto Light SPEC ERBB2/CEN 17 Dual Color Probe C€ IVD	•/•	20 (200 µl)	
Z-2190-50	Zyto Light SPEC ERBB2/D17S122 Dual Color Probe C € IVD	•/•	5 (50 µl)	
Z-2190-200	Zyto Light SPEC ERBB2/D17S122 Dual Color Probe C € IVD	•/•	20 (200 µl)	
Z-2020-5	Zyto Light SPEC ERBB2/CEN 17 Dual Color Probe Kit C (IVD) Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 210 ml; Probe, 0.05 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml	•/•	5	
Z-2020-20	Zyto Light SPEC ERBB2/CEN 17 Dual Color Probe Kit C (IVD) Incl. Heat Pretreatment Solution Citric, 500 ml; Pepsin Solution, 4 ml; Wash Buffer SSC, 560 ml; Probe, 0.2 ml; 25x Wash Buffer A, 100 ml; DAPI/DuraTect-Solution, 0.8 ml	•/•	20	
Related Products				
Z-2028-5	Zyto Light FISH-Tissue Implementation Kit Incl. Heat Pretreatment Solution Citric, 150 ml; Pepsin Solution, 1 ml; Wash Buffer SSC, 210 ml; 25x Wash Buffer A, 50 ml; DAPI/DuraTect-Solution, 0.2 ml		5	

* Using 10 µl probe solution per test. CE IVD only available in certain countries. All other countries research use only! Please contact your local dealer for more information.

Zyto*Light* ® Fluorochromes

- · Fluorochromes of the FISH probes
- Appropriate filter sets

Fluorochrome	Excitation	Emission	Equivalent to
 ZyGreen™ 	503 nm	528 nm	FITC
 ZyOrange[™] 	547 nm	572 nm	Rhodamine

Recommended Filter Sets

noise ratio and need to be assembled contact info@zytovision.com for more

Prod. No	Product	Detected Fluorochrome
E-4030-1	DAPI Single Bandpass Filter Set v2	DAPI
E-4012-1	ZyGreen™ Single Bandpass Filter Set v2	•
E-4013-1	ZyOrange™ Single Bandpass Filter Set v2	•
E-4016-1	ZyGreen™/ZyOrange™ Dual Bandpass Filter Set v2	•/•
E-4010-1	DAPI/ZyGreen™/ZyOrange™ Triple Bandpass Filter Set	DAPI/•/•